Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
--Topline data from cUTI and uUTI pivotal trials on track to report around the end of Q1-- --NDAs anticipated to file with the FDA in mid-2020-- DUBLIN, Ireland and CHICAGO, March 12, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a …